. Author manuscript; available in PMC: 2022 Sep 1.

Published in final edited form as: Neurotoxicol Teratol. 2021 May 1;87:106993. doi: 10.1016/j.ntt.2021.106993

Table 3:

Multiple Dose Neuropathology Results

Compound	Dose mg/kg	Route of administration	% animals with vacuolization			% animals with necrosis			% animals with increased Iba-1 labelling			% animals with increased GFAP staining
			3h	363 h	432 h	3 h	363 h	432 h	3h	363 h	432 h	3h	363 h	432 h
Negative control	NA	IV^a	0%			0%			0%			0%
(2R,6R)-HNK	12	IV^a	0%			0%			0%			0%
(2R,6R)-HNK	80	IV^a	0%			0%			0%			0%
(2R,6R)-HNK	160	IV^a	0%			0%			0%			0%
Ketamine	50	IP^b	0%			0%			0%			0%
Ketamine	60	IP^b	0%			0%			0%			0%
MK-801	0.5	SC^c	0%	0%	0%	0%	60%	40%	0%	70%	10%	0%	80%	80%
MK-801	0.8	SC^c	30%	0%	0%	0%	100%	90%	0%	90%	40%	0%	100%	100%

Ten animals/sex/group per timepoint per sex were utilized. The negative control and (2R,6R)-HNK groups utilized both male and female animals. The ketamine andMK-801 groups utilized only female animals.363 hours represents Day 15, + 3 hours. 432 hours represents Day 15 + 72 hours

Administered as an intravenous infusion over 20 minutes.

Intraperitoneal injection.

Subcutaneous dosing.